B&L Retisert Drug Delivery Implant FDA Filing Delayed By One Year
This article was originally published in The Gray Sheet
Executive Summary
Bausch & Lomb will wait for results from its second pivotal trial for the Retisert drug-delivery implant for treating posterior uveitis before submitting a new drug application to FDA, which is expected in mid-2004
You may also be interested in...
B&L Expanded Drug-Delivery Products Seen As Springboard To Future Growth
Bausch & Lomb continues to transform itself into a drug-delivery eyecare company from a traditional contact lens firm, with implants and molecular compounds in various stages of development
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.